Immunogenicity and reactogenicity of a group C meningococcal conjugate vaccine compared with a group A+C meningococcal polysaccharide vaccine in adolescents in a randomised observer-blind controlled trial

Vaccine

Volumn 18, Issue 24, 2000, Pages 2686-2692

  Choo, Sharon ^a   Zuckerman, Jane ^b   Goilav, Christian ^c   Hatzmann, Eva ^d   Everard, Jan ^a   Finn, Adam ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c CHIRON VACCINES   (Italy)

^d Chiron Vaccines   (Netherlands)

Author keywords

Meningococcal; Neisseria meningitidis; Vaccines, Conjugate

Indexed keywords

MENINGOCOCCUS VACCINE; POLYSACCHARIDE VACCINE;

ADOLESCENT; ARTICLE; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; DRUG SAFETY; FEMALE; FEVER; HEADACHE; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; IMMUNOGENICITY; IMMUNOLOGICAL MEMORY; MALE; MENINGOCOCCOSIS; MYALGIA; NEISSERIA MENINGITIDIS; NORMAL HUMAN; PAIN; PRIORITY JOURNAL; SCHOOL CHILD; SEROTYPE;

EID: 0034213183     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(00)00050-5     Document Type: Article

References (26)

1. Ramsay M., Kaczmarski E., Rush M., Mallard R., Farrington P., White J. Changing patterns of case ascertainment and trends in meningococcal disease in England and Wales. CDR Review. 7:1997;R49-R54.
2. Connolly M., Noah N. Is group C meningococcal disease increasing in Europe? A report of surveillance of meningococcal infection in Europe 1993-6. Epidemiology and Infection. 122:1999;41-49.
3. Whalen C.M., Hockin J.C., Ryan A., Ashton F. The changing epidemiology of invasive meningococcal disease in Canada, 1985 through 1992. Emergence of a virulent clone of Neisseria meningitidis. JAMA. 273:1995;390-394.
4. Kaczmarski E.B. Meningococcal disease in England and Wales: 1995. CDR Review. 4:1997;R55-R59.
5. Enhanced surveillance of suspected meningococcal disease. CDR Weekly. 9:1999;192.
6. King W.J., MacDonald N.E., Wells G., et al. Total and functional antibody response to a quadrivalent meningococcal polysaccharide vaccine among children. J. Pediatr. 128:1996;196-202.
7. Granoff D.M., Gupta R.K., Belshe R.B., Anderson E.L. Induction of immunologic refractoriness in adults by meningococcal C polysaccharide vaccination. J. Infect. Dis. 178:1998;870-874.
8. Artenstein M.S., Brandt B.L. Immunologic hyporesponsiveness in man to group C meningococcal polysaccharide. J. Immunol. 115:1975;5-7.
9. Brandt B.L., Artenstein M.S. Duration of antibody responses after vaccination with group C Neisseria meningitidis polysaccharide. J. Infect. Dis. 131:(Suppl):1975;S69-72.
10. Lepow M.L., Goldschneider I., Gold R., Randolph M., Gotschlich E.C. Persistence of antibody following immunization of children with groups A and C meningococcal polysaccharide vaccines. Pediatrics. 60:1977;673-680.
11. Anderson E.L., Bowers T., Mink C.M., et al. Safety and immunogenicity of meningococcal A and C polysaccharide conjugate vaccine in adults. Infect. Immun. 62:1994;3391-3395.
12. Twumasi P.A. Jr, Kumah S., Leach A., et al. A trial of a group A plus group C meningococcal polysaccharide-protein conjugate vaccine in African infants. J. Infect. 171:1995;632-638.
13. Lieberman J.M., Chiu S.S., Wong V.K., et al. Safety and immunogenicity of a serogroups A/C Neisseria meningitidis oligosaccharide-protein conjugate vaccine in young children. A randomized controlled trial. JAMA. 275:1996;1499-1503.
14. Fairley C.K., Begg N., Borrow R., Fox A.J., Jones D.M., Cartwright K. Conjugate meningococcal serogroup A and C vaccine: reactogenicity and immunogenicity in United Kingdom infants. J. Infect. Dis. 174:1996;1360-1363.
15. Leach A., Twumasi P.A., Kumah S., et al. Induction of immunological memory in Gambian children by vaccination in infancy with a Group A plus Group C meningococcal polysaccharide-protein conjugate vaccine. J. Infect. Dis. 175:1997;200-204.
16. MacDonald N.E., Halperin S.A., Law B.J., Forrest B., Danzig L.E., Granoff D.M. Induction of immunologic memory by conjugated vs plain meningococcal C polysaccharide vaccine in toddlers. JAMA. 280:1998;1685-1689.
17. Richmond P., Borrow R., Miller E., et al. Meningococcal serogroup C conjugate vaccine is immunogenic in infancy and primes for memory. J. Infect. Dis. 179:1999;1569-1572.
18. Granoff D.M., Maslanka S.E., Carlone G.M., et al. A modified enzyme-linked immunosorbent assay for measurement of antibody responses to meningococcal C polysaccharide that correlate with bactericidal responses. Clinical and Diagnostic Laboratory Immunology. 5:1998;479-485.
19. Goldschneider I., Gotschlich E.C., Artenstein M.S. Human immunity to the meningococcus. I. The role of humoral antibodies. J. Exp. Med. 129:1969;1307-1326.
20. Vaccination programme for group C meningococcal infection is launched. CDR Weekly. 9:1999;261.
21. Gold R., Artenstein M.S. Meningococcal infections. 2. Field trial of group C meningococcal polysaccharide vaccine in 1969-70. Bull. World Health Organ. 45:1971;279-282.
22. Rosenstein N., Levine O., Taylor J.P., et al. Efficacy of meningococcal vaccine and barriers to vaccination. JAMA. 279:1998;435-439.
23. Masterton R.G., Youngs E.R., Wardle J.C., Croft K.F., Jones D.M. Control of an outbreak of group C meningococcal meningitis with a polysaccharide vaccine. J. Infect. 17:1988;177-182.
24. Artenstein M.S., Gold R., Zimmerly J.G., Wyle F.A., Schneider H., Harkins C. Prevention of meningococcal disease by group C polysaccharide vaccine. N. Engl. J. Med. 282:1970;417-420.
25. Kayhty H, MacLennan JM, Nurkka A et al. Salivary antibodies after revaccination with meningococcal (Men) A/C polysaccharide vaccine (MPS) following repeated immunisation during early childhood. In: 11th International Pathogenic Neisseria Conference, 1998. vol. 215. (Abstract).
26. Choo S, Zhang Q, Everard J et al. Serum and Mucosal Immunity to Meningococcal Vaccines in UK Adolescents. In: 17th Annual Meeting of the European Society for Paediatric Infectious Diseases, 1999. vol. 30. (Abstract).